U.S. regulators have warned Johnson & Johnson unit Janssen Pharmaceutica that a letter sent to doctors about its Risperdal drug to treat schizophrenia and bipolar mania is misleading. In a warning disclosed on Tuesday, the Food and Drug Administration told Janssen that its November letter failed to disclose information added to Risperdal’s labeling about excess blood sugar and diabetes and minimized the risk of serious events including coma and even death. The FDA also said the letter fails to recommend regular testing for diabetes and “misleadingly claims that Risperdal is safer than other atypical antipsychotics.”

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 27 Apr 2004
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2004). J&J Warned on Claims About Antipsychotic Drug. Psych Central. Retrieved on September 18, 2014, from http://psychcentral.com/blog/archives/2004/04/27/jj-warned-on-claims-about-antipsychotic-drug/

 

Recent Comments
  • dylan semper: 10. Do not blame yourself for their issues.
  • Lauren T.: One part of this article that caught my attention was the term “thin-heritance”. I think that...
  • buy high pr backlinks: As someone, who celebrated a year of recovery, it was these campaigns that helped me out, and...
  • John M. Grohol, Psy.D.: I’m sorry, but it’s a bit disingenuous (and unbelievable) to suggest that a...
  • This Guy: So many things to say to this article, but I’ll stick to one: I wonder, would you have the same...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code